Cigna HealthCare, NCH team up to deliver quality care related to cancer

New Century Health (NCH) and Cigna HealthCare of Arizona today announced an alliance focused on delivering quality care related to cancer. Cigna customers covered under Arizona Medicare Advantage plans who receive care through the Cigna Medical Group (CMG) are included in this new program with NCH.

"Customers belong at the center of a health system that promotes quality and improves both affordability and satisfaction," said Edward Kim, President and General Manager of Cigna HealthCare of Arizona and Cigna Medical Group. "Cigna and NCH are dedicated to achieving improved care for the patients we serve. This new collaboration will support a more seamless, quality health experience that is simpler and specifically directed towards cancer diagnosis and treatment."

"We are excited to work with CIGNA to improve the quality of cancer care for their members," said Atul Dhir, MD, DPhil, and Chief Executive Officer of New Century Health. "With the advances in the treatments for cancer, NCH's goal is to provide the capabilities to the physicians and payers to ensure that the highest quality, evidence based treatments are provided in an efficient and cost effective manner."

Cigna Medical Group is working with health care organizations across Maricopa County to develop programs and services that support value-driven, patient-centered care for all of its Cigna health care customers. 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Machine learning model predicts CDK4/6 inhibitor effectiveness in metastatic breast cancer